86
· DOS Abstracts
Long - term results of total joint arthroplasties with
Elektra prothesis in trapeziometacarpal osteoarhritis
Barbara Kulinski
Hand Unit, Southern Jutland Hospital
Background:
The Elektra prothesis is a cementless prothesis used in trapezio-
metacarpal osteoarthritis.Early follow-up studies showed fast recovery and
good functional results.Later studies with longer follow-up indicated severe
problems with implant survival.
Purpose / Aim of Study:
To report our long-term results with the Elektra TMC
prothesis
Materials and Methods:
Between 2005 -2009 14 TMC joints in 13 patients
(3 men,10 women) with a mean age of 52(range 40-73) years were operated
using the Elektra prothesis.All patients were diagnosed with symptomatic and
radiological TMC oeteoarthritis, Eaton- Littler stage 2 and 3.One hand surgeon
performed all operations.Clinical and radiological follow-up were performed at
3 weeks,12 weeks,52 weeks postoperatively.In 2014 two hand surgeons ex-
amined all implants still in place with radiographs, grip/pinch strength and pa-
tient perceived outcome. Blood samples were analysed for serum cobalt and
chrome.
Findings / Results:
4 implants(28%) had been revised because of dislocation
of the neck 34 months(range 3-70)postoperatively.The necks were changed
to longer ones,however in two patients the protheses later had to be removed.
One patient had the prothesis removed after trauma. In two patients revision
with trapezectomy was performed due to loose cup after 7 and 36 months.
After mean follow-up of 93 months (range 60-108) 8 patients with 9 retaining
implants (62%) were available for follow-up.Radiographs showed no loosening,
mean quickDASH was12 (range 0-32 ),mean pinch strength was 6.5 (range
4-9)kg,mean grip strength was 30.6(range 20-42)kg.Mobility was excellent in
all patients.2 patients had elevated serum cobalt and chrome values.
Conclusions:
We found a high revision rate but excellent functional result in
the surviving protheses. Due to high revison rate the Elektra prothesis should be
used in selected patients.
33.
